<DOC>
	<DOCNO>NCT01098539</DOCNO>
	<brief_summary>This randomize , double-blind , active-controlled study evaluate efficacy safety weekly dose albiglutide compare sitagliptin . Subjects renally impaired historical diagnosis type 2 diabetes mellitus whose glycemia inadequately control current regimen diet exercise antidiabetic therapy metformin , thiazolidinedione , sulfonylurea , combination oral antidiabetic medication recruit study .</brief_summary>
	<brief_title>A Study Efficacy Safety Albiglutide Subjects With Type 2 Diabetes With Renal Impairment .</brief_title>
	<detailed_description>This randomize , double-blind , active-controlled , 2 parallel-group , multicenter study evaluate efficacy safety weekly subcutaneously inject dose albiglutide compare sitagliptin . Subjects renally impaired historical diagnosis type 2 diabetes mellitus whose glycemia inadequately control current regimen diet exercise antidiabetic therapy metformin , thiazolidinedione , sulfonylurea , combination oral antidiabetic medication recruit study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Renally impaired historical diagnosis type 2 diabetes mellitus experience inadequate glycemic control current regime diet exercise antidiabetic therapy metformin , TZD , SU , combination oral antidiabetic medication BMI &gt; /=20 kg/m2 &lt; /=45 kg/m2 Fasting Cpeptide &gt; /=0.8 ng/mL ( &gt; /=0.26 nmol/L ) HbA1c 7.0 % 10.0 % , inclusive . History cancer History treat diabetic gastroparesis Current biliary disease history pancreatitis History significant gastrointestinal surgery Recent clinically significant cardiovascular and/or cerebrovascular disease History human immunodeficiency virus infection Abnormal liver function acute symptomatic infection hepatitis B hepatitis C Female subject pregnant ( confirmed laboratory test ) , lactate , &lt; 6 week postpartum Known allergy GLP 1 analogue , sitagliptin , study medication ' excipients , excipients albiglutide , Baker 's yeast Receipt investigational drug sitagliptin within 30 day 5 half life , whichever longer , Screening history receipt investigational antidiabetic drug within 3 month randomization receipt albiglutide previous study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>sitagliptin</keyword>
	<keyword>albiglutide</keyword>
	<keyword>renal impairment</keyword>
</DOC>